References
- Carlson JA. Nafcillin-resistant staphylococci: epidemiology, identification, treatment and control. Hosp Formul 1984: 19(Oct): 960–74
- Janknegt R. Fluorinated quinolones: a review of their mode of action, antimicrobial activity, pharmacokinetics and clinical efficacy. Pharm Weekbl [Set] 1986: 8(1): 1–21
- Fass RJ. The quinolones. (Editorial) Ann Intern Med 1985: 102(3): 400–2
- Adhami ZN, Wise R, Weston D, et al. The pharmacokinetics and tissue penetration of norfloxacin. J Antimicrob Chemother 1984: 13(1): 87–92
- Neuman M. Comparative pharmacokinetic parameters of new systemic fluoroquinolones. Int J Clin Pharmacol Res 1987: 7(3): 173–9
- Burman LG. Apparent absence of transferable resistance to nalidixic acid in pathogenic Gramnegative bacteria. J Antimicrob Chemother 1977: 3(5): 509–16
- Sanders CC, Sanders WE Jr, Goering RV, et al. Selection of multiple antibiotic resistance by quinolones, beta-lactams, and aminoglycosides with special reference to cross-resistance between unrelated drug classes. Antimicrob Agents Chemother 1984: 26(6): 797–801
- Wolfson JS, Hooper DC The fluoroquinolones: structures, mechanisms of action and resistance, and spectra of activity in vitro. Antimicrob Agents Chemother 1985: 28(4): 581–6
- Kayser FH. The quinolones: mode of action and mechanism of resistance. Res Clin Forums 1985: 7: 17–27
- Auckenthaler R, Michea-Hamzehpour M, Pechere JC In-vitro activity of newer quinolones against aerobic bacteria. J Antimicrob Chemother 1986: 17(Suppl B): 29–39
- Chow AW, Cheng N, Bardett KH. In vitro susceptibility of Clostridium difficile to new betalactam and quinolone antibiotics. Antimicrob Agents Chemother 1985: 28(6): 842–4
- Carver PL, Fekety R. The quinolones: expanded choices and individual differences. Consultant 1988: 28(7): 59–63, 66–7
- Kaatz GW, Barriere SL, Schaberg DR, et al. Ciprofloxacin versus vancomycin in the therapy of experimental methicillin-resistant Staphylococcus aureus endocarditis. Antimicrob Agents Chemother 1987: 31(4): 527–30
- Watt B, Brown FV. Is ciprofloxacin active against clinically important anaerobes? J Antimicrob Chemother 1986: 17(5): 605–13
- Johnson PC, Ericsson CD, Morgan DR, et al. Lack of emergence of resistant fecal flora during successful prophylaxis of travelers diarrhea with norfloxacin. Antimicrob Agents Chemother 1986: 30(5): 671–4
- Dan M, Golomb J, Gorea A, et al. Concentration of ciprofloxacin in human prostatic tissue after oral administration. Antimicrob Agents Chemother 1986: 30(1): 88–9
- Greenberg RN, Kennedy DJ, Reilly PM, et al. Treatment of bone, joint, and soft-tissue infections with oral ciprofloxacin. Antimicrob Agents Chemother 1987: 31(2): 151–5
- Smith CR. The adverse effects of fluoroquinolones. J Antimicrob Chemother 1987: 19(6): 709–11
- Barriere SL, Neu HC. Economic implications of oral ciprofloxacin therapy. Infect Med 1987: (Suppl): 14
- Maesen FP, Teengs JP, Baur C, et al. Quinolones and raised plasma concentrations of theophylline. (Letter) Lancet 1984: 2(8401): 530